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Involvement of transcriptional mechanisms in the inhibition of NOS2
expression by dexamethasone in rat mesangial cells. In previous studies
we reported that stimulation of rat mesangial cells (RMC) with lipopoly-
saccharide (LPS) 1 tumor necrosis factor alpha (TNF-a) (L/T) elicits
inducible nitric oxide synthase (NOS2) mRNA expression, which is
inhibited by dexamethasone (DX). We have now analyzed the mecha-
nisms responsible for this inhibitory effect. Dexamethasone had no
destabilizing effect on NOS2 mRNA. Transfection of RMC with several
luciferase reporter constructs from the 59 flanking regulatory region of the
rat NOS2 gene established the importance of the NF-kB site in the
transcriptional activation of the NOS2 gene. DNA mobility shift assays
showed activation by L/T of the NF-kB complex in a time-dependent
manner. Dexamethasone specifically inhibited this activation in a process
dependent on the glucocorticoid receptor and with a markedly greater
effect when it was added prior to L/T. Dexamethasone increased the
expression of the IkB-a transcript and protein in the cytoplasm. While
treatment of RMC with L/T induced the transient decrement of cytoplas-
mic p65 levels and its appearance in the nucleus, preincubation with DX
prevented this effect. Co-immunoprecipitation and immunocytochemical
studies demonstrated that IkB-a is associated with p65 in the cytoplasm of
RMC after treatment with DX and L/T. These results prove that inhibition
of NF-kB-mediated transcription is a crucial mechanism by which DX
inhibits NOS2 expression, and that this occurs by increasing cytoplasmic
IkB-a levels and sequestering the activating subunits of NF-kB in the
cytoplasm. The need for previous induction of IkB-a could provide a
molecular explanation for the limited efficacy of these agents in the
therapy of septic shock.
Nitric oxide (NO) is a labile free radical with varied biological
functions, including neurotransmission, vasodilation and partici-
pation in the nonadaptive immune response, [1]. Its synthesis
occurs through the oxidation of one of the guanidino groups of
L-arginine and also yields L-citrulline as a co-product. The group
of enzymes that catalyze this reaction are termed nitric oxide
synthases (EC 1.14.13.39). Three isoforms, named NOS1 (neuro-
nal or nNOS), NOS2 (inducible or iNOS) and NOS3 (endothelial
or ecNOS) sharing in common functional and structural proper-
ties, have been identified. In terms of the regulation of their
expression these enzymes are, nevertheless, markedly different
[2]. NOS2 is an enzyme involved in the high output synthesis of
NO in cells or tissues that have been exposed to extracellular
stimuli. In mammals, the synthesis of NO by this enzyme is
believed to be critical in pathophysiological conditions such as
inflammation and septic shock [3]. In inflammatory scenarios NO
may serve defense functions, contributing to the killing of infec-
tive intracellular organisms or tumor cells. In septic shock, NO
may contribute to the hemodynamic imbalance and high mortality
of its final stages, a concept supported by studies in NOS2-
deficient mutant mice [4, 5]. Thus, knowledge of the pharmaco-
logical regulation of NOS2 expression becomes important in
order to design strategies to maintain NO synthesis at non-
harmful levels. NOS2 is mainly regulated at the level of transcrip-
tion [6]. A fairly large number of substances have been described
to up- or down-regulate NOS2 mRNA expression either by acting
on mRNA stability or on the transcription rate [7]. Among these
substances, glucocorticoids were one of the first to be shown to
down-regulate NO synthesis and NOS2 expression [8, 9]. The
recent characterization of the 59 flanking regulatory region of the
NOS2 gene permits the exploration of the precise molecular
mechanisms of the glucocorticoid effects. In the promoter regions
characterized so far in the NOS2 genes, no sequences similar to
the glucocorticoid responsive element have been described [10–
12]. Hence, the molecular pathways by which these agents exert
their effect on NOS2 transcription remain incompletely under-
stood.
Mesangial cells have well characterized physiological functions
in the kidney glomeruli [13], and are the main players in their
inflammatory response. They have been shown to synthesize NO
under several stimuli [14, 15], and possible sources and roles of
this mediator in glomerulonephritis has been brought up in the
past several years [16]. In this study, we investigated the potential
mechanisms for the glucocorticoid inhibition of NOS2 expression
in rat mesangial cells. Our results offer experimental evidence to
support the concept that glucocorticoids suppress NOS2 expres-
sion in a process where their interaction with the NF-kB family of
proteins is an essential step to inactivate transcription of the
NOS2 gene.
1 M. Saura and C. Zaragoza contributed equally to this article.
Key words: Nitric oxide synthase, mesangial cells, transcription, glucocor-
ticoids, NF-kB.
Received for publication February 3, 1997
and in revised form August 5, 1997
Accepted for publication August 6, 1997
© 1998 by the International Society of Nephrology
Kidney International, Vol. 53 (1998), pp. 38–49
38
METHODS
Reagents
Recombinant human tumor necrosis factor (rHuTNF-a, 9.8 3
106 U/mg) was a gift from Knoll Pharmaceuticals (Whipanny, NJ,
USA); cell culture media, fetal calf serum and media supplements
were from Gibco (Paisley, Scotland, UK). Taq polymerase was
from Promega (Madison, WI, USA), and dNTPs from Gibco
BRL; deoxycytidine 59-triphosphate (a-32P; 3000 Ci/mmol) was
from Amersham (Buckinghamshire, UK); RU-486 (Mifepristone)
was a gift from Roussel-UCLAF (Romainville, France). All other
reagents, including lipopolysaccharide (LPS) E. coli serotype
0127:B8, dexamethasone and pyrrolidine dithiocarbamate
(PDTC), were from Sigma Chemical (St. Louis, MO, USA).
Polyclonal antibodies against the human c-Rel protein and N-
termini of human p65 and p50 proteins were kindly provided by
Dr. Nancy Rice (National Cancer Institute, Bethesda, MD, USA).
The antibody against IkB-a was from Santa Cruz Biotechnologies
(Santa Cruz, CA, USA).
Plasmids
Plasmid kB (33) con A-LUC contained three copies of the kB
motif from the HIV enhancer with no enhancer element of the
conalbumin promoter [17]. RSV-b GAL was an expression vector
of b-galactosidase under control of the Rous sarcoma virus
promoter. The plasmid containing the cDNA for IkB-a was a gift
of M.T. Dı´az-Meco and J. Moscat (Centro de Biologı´a Molecular,
Madrid, Spain).
Cell culture
Rat mesangial cells were characterized as described [18]. Cells
were used between passages 2 and 10. They were cultured in 100
mm plates at 37°C with 5% CO2 and fed every 48 hours with
RPMI 1640 supplemented with 10% fetal calf serum, L-glutamine
(2 mM), penicillin (50 U/ml), and streptomycin (50 mg/ml).
Potential toxicity of reagents on RMC was ruled out by trypan
blue exclusion (. 90% of cells were viable) and measurements of
LDH release to the cell culture media.
RNA isolation and Northern blot analysis
Total cellular RNA was isolated from RMC with the guani-
dinium thiocyanate-phenol-chloroform method [19], size-frac-
tionated by electrophoresis (10 mg/lane) through denaturing 1%
agarose-0.66 M formaldehyde gels, transferred to Hybond hybrid-
ization transfer membranes (Amersham, UK), and UV cross-
linked before hybridization as previously described [20]. A 699 bp
fragment corresponding to the NOS2 cDNA was obtained from
total RNA of stimulated RMC, using reverse transcriptase fol-
lowed by polymerase chain reaction (RT-PCR). The following
primers were used for amplification: sense: 59 GAGAGATCC
GATTTAGAGTCT 39; antisense: 59 GCAGATTCTGCTGGGA-
TTTCA 39. Polymerase chain reaction was performed for 35
cycles, each consisting of one minute at 94°C, one minute at 55°
and one minute at 72°C. This 699 bp fragment was submitted to
manual and automatic sequencing, and its nucleotide sequence is
available at the Genbank database (Accession number U48829).
For Northern analysis, it was labeled with [a-32P]dCTP and
random hexamers, using a commercial kit (Boehringer Mann-
heim, Germany). For the Northern blot analysis of IkB-a, we used
a BamHI/HindIII 1.4 kb fragment of the rat IkB-a cDNA labeled
as above. Hybridization was performed at 42°C for 12 to 16 hours,
membranes were then washed at final stringency conditions of
55°C, 0.2 3 SSC, 0.1% SDS and exposed with XAR Kodak film,
using an intensifying screen. Blots were rehybridized with a
b-actin cDNA probe [21]. Densitometric analysis was performed
on an Apple scanner using Image 1.55 (NIH, Bethesda, MD,
USA). Results are expressed in arbitrary units as the ratio of
NOS2/b-actin expression.
Cloning of 5*-flanking region of rat NOS2
To isolate a 59 flanking region fragment from the rat NOS2
gene, PCR was performed using the following set of primers:
sense (iNOSRP1): 59 CCAGAGAGCTCCGTGCCCAG 39; anti-
sense (iNOSRP2): 59 GGAAGC TTGTGGGGCCAGAGTCT-
CA 39. iNOSRP1 (20-mer) was selected from the reported
macrophage murine regulatory region [11] (positions 2338 to
2319). Sequence of the iNOSRP2 primer was based on the
previous cloned rat iNOS cDNA [22, 23], which is identical to the
homologous murine gene. A HindIII restriction site was added to
the 59 region of the iNOSRP2 oligomer. A 388 bp PCR fragment
amplified from rat genomic DNA with the above-cited oligomers,
hybridized with the 1749 bp reported 59 murine NOS2 regulatory
region. The fragment was cloned into a luciferase reporter
plasmid (PGL-3 basic; Promega, Madison, WI, USA) (380-
piNOS-LUC) and several clones were sequenced manually on
both strands with the dideoxy protocol (Sequenase version 2.0
DNA sequencing kit; Amersham) and with a Perkin-Elmer 377
automatic sequencer. Sequence analysis and search for transcrip-
tion factors binding sites were done using the Findpatterns
algorithm from the database of the Genetics Computer Group
(Madison, WI, USA). An additional 727 bp fragment from the
59 flanking region of the rat iNOS gene was cloned by PCR
using the same antisense primer (iNOSRP2) and a sense primer
(iNOSRP3): 59 CCACCAGACCTAGGTAGGGT 39 located at
the 2710 to 2693 positions of the rat iNOS promoter [24]. A SacI
restriction site was added in order to clone the fragment in the
PGL-3 plasmid (720-piNOS-LUC). The 720 bp rat iNOS pro-
moter fragment containing the mutated NF-kB site was con-
structed using PCR. An antisense primer carrying the mutation in
the NF-kB motif (iNOSRPmut.): 59 ATAACTGTTCCCAAAG-
GGAGAGTAACCAGTTATCGATGAA TTC 39 was used with
the sense iNOSRP3 described above to amplify a 700 bp fragment
that was digested with SacI/PstI and inserted upstream of the
TATA box in the original -700-iNOS-PGL-3 construct (720
(NF-kB mut)-piNOS-LUC).
Transient transfections and luciferase assay
In initial experiments RMC were transfected by a liposome-
mediated method (DOTAP reagent, B.; Mannheim, Germany).
Two 3 106 RMC were transfected with 380-piNOS-LUC and
RSV-bGAL using a 5 mg DNA/10 mg liposome ratio during six
hours in serum-reduced medium. Sixteen hours after transfection,
cells were treated with the corresponding reagents during 48
hours. Plates were incubated with reporter lysis buffer (Promega,
Madison, WI, USA) and cells were processed as recommended by
the manufacturer. Light output was measured during 10 seconds
with an LKB-Wallac 1250 luminometer (Pharmacia, Uppsala,
Sweden). Luciferase activity was normalized for variations in
transfection efficency as determined by b-galactosidase activity
measurements [25]. In subsequent experiments a dual-luciferase
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reporter assay was used. In this procedure RMC (1 3 106 cells/60
mm culture dish) were co-transfected by a liposome-mediated
method (lipofectin; Gibco BRL) with 380-piNOS-LUC, 720-
piNOS-LUC or 720 (NF-kB mut)-piNOS-LUC and a second
reporter vector (pRL-SV40 vector containing the Renilla lucif-
erase gene (Promega, Madison, WI, USA) using a 5 mg DNA/10
mg liposome ratio during six hours in serum-reduced medium; 16
hours after transfection, cells were treated with the corresponding
reagents during 48 hours. Cellular lysates were prepared with 400
ml of passive lysis buffer (Promega) and cells were processed as
recommended by the manufacturer. Light output from firefly and
Renilla luciferases was measured over 10 seconds of integration
period of each luciferase reaction. Firefly luciferase activity was
normalized for variations in transfection efficency as determined
by the Renilla luciferase activity measurements. Protein content
was assayed by the Bradford method by using a BioRad dye
reagent (Richmond, CA, USA). Transfections were done in
duplicate and each experiment was repeated at least three times.
Preparation of nuclear extracts
A modification of the method of Schreiber et al was used [26].
Rat mesangial cells (RMC) were washed twice with PBS buffer,
scraped in PBS and transferred to microcentrifuge tubes. Cell
pellets were resuspended in 400 ml of buffer A containing: 10 mM
Hepes, pH 7.9, 10 mM KCl, 10 mM EDTA, 10 mM EGTA, 1 mM
dithiotreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF) and 1 mg/ml of leupeptin, antipain, trypsin inhibitor and
pepstatin A. After 10 minutes at 4°C, NP-40 was added to reach
a final concentration of 2%. Tubes were vigorously vortexed for 10
seconds and nuclei sedimented by centrifugation for 30 seconds in
a microfuge. Nuclear pellets were resuspended in 50 ml of buffer
C: 20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA,1 mM EGTA,
1 mM DTT, 5 mM MgCl2, 25% glycerol, 1 mM PMSF and protease
inhibitors at 1 mg/ml, by gently shaking at 4°C. After centrifuga-
tion at 13,000 3 g for 15 minutes, nuclear debris was discarded
and aliquots of the supernatant, containing the nuclear proteins,
were stored at 280°C. Protein content was determined by the
Bradford method as described above.
Electrophoretic mobility shift assays (EMSAS)
Oligonucleotides were synthesized in a Beckman Oligo 1000 M
DNA synthesizer. The oligonucleotide sequence corresponding to
the consensus sequence for binding of NF-kB, based on the rat
NOS2 promoter, was:
59 CCTACTGGGGACTCTCCCTTTG 39
39 GGATGACCCCTGAGAGGGAAAC 59
Primers were annealed by incubation for five minutes at 85°C in
phosphate buffer 10 mM, pH 7, and slowly cooled down to room
temperature; 2 pmol of these primers were end-labeled using T4
polynucleotide kinase (Promega) in the presence of 10 mCi of
Fig. 1. Effect of dexamethasone (DX) and RU-
486 on NOS2 mRNA expression in rat
mesangial cells (RMC). The RMC were treated
with vehicle (CT); lipopolysaccharide (LPS; 10
mg/ml, 8 hr) 1 TNF-a (L/T; 100 ng/ml, 8 hr);
DX (1026 M, 8 hr); RU-486 (RU; 10 mM, 8 hr);
DX 1 L/T and DX 1 L/T 1 RU-486. Total
RNA was extracted and hybridized with NOS2
(upper panel) and b-actin (middle panel)
probes as described. Shown in the lower panel
is the densitometric analysis of NOS2 mRNA
expression after correction by the expression of
b-actin. The data are representative of three
independent experiments. *P , 0.05 versus
control.
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(32P)-g-ATP. For binding reaction 1 to 2 3 104 cpm of end-
labeled oligonucleotide probes were incubated with 10 mg of
nuclear extract and 1 mg of poly(dI.dC) in binding buffer (4%
glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0,5 mM DTT, 50 mM NaCl,
10 mM Tris-HCl, pH 7.5) at room temperature for 30 minutes.
Protein-DNA complexes were separated by electrophoresis in a
4% non-denaturing polyacrylamide gel and visualized by autora-
diography.
For competition experiments 200-fold molar excess of compet-
itor DNA was incubated in the mixture prior to the addition of
nuclear extracts. When supershift assays were carried out, poly-
clonal antibodies against specific NF-kB subunits were added to
the extracts 10 minutes prior to the probe.
Western blot and immunoprecipitation assays
Total cellular proteins were isolated using standard methods
[27]. In brief, cellular monolayers were washed with PBS and
harvested in protein lysis buffer (1% Triton X-100, 10 mM
Tris/HCl, pH 7.6, 1 mM EDTA, 0.1% sodium deoxycholate, 500
nM sodium orthovanadate, 50 mM NaF, 0.5 mM PMSF, and 1
mg/ml of antipain and leupeptin). Lysates were centrifuged (1500
g, 5 min) in a microfuge and the supernatant was collected.
Protein concentration was determined by the Bradford method.
Two hundred micrograms of total protein were separated in a
SDS-polyacrylamide gel electrophoresis (10% for IkB-a and 8%
for p65) and transferred to a PDVF membrane (Polyscreen;
Dupont, Wilmington, DE, USA). For protein detection, blocked
membranes were incubated first, with anti-IkB-a or anti-p65
antibodies in 3% BSA in PBS during one hour, washed and
incubated with a secondary antibody. After extensive washing,
ECL detection was performed according to the manufacturer’s
procedures (Amersham).
For the immunoprecipitation assays cytoplasmic extracts (150
to 200 mg) were pre-cleared with rat IgG non-immune antisera
and protein A/G sepharose (Santa Cruz Biotechnologies) for two
hours at 4°C. After centrifugation (1500 g, 5 min, 4°C), the
supernatants were incubated with anti-human IkB-a antibody (1
mg) or preimmune serum, overnight at 4°C. Complexes were then
incubated with protein A/G sepharose for four hours at 4°C with
gentle rocking. Protein A/G sepharose immunocomplexes were
successively washed four times with low stringency buffer (100 mM
Hepes, pH 7.6, 250 mM NaCl, 5 mM EDTA, 0.25% Nonidet P-40).
Proteins were eluted by incubation with 200 ml of elution buffer
(20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1% SDS, 5 mM dithio-
threitol) for 10 minutes at 95°C. Supernatants were diluted with
200 ml of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1% Nonidet P-40
and 1% sodium deoxycholate, divided into two aliquots and
subjected to a second round of immunoprecipitation using anti-
P65 or anti-IkB-a antibodies and 20 ml of protein A/G agarose
during four hours at 4°C. Specific immunocomplexes were washed
three times with RIPA buffer (phosphate buffer saline, 1%
Nonidet P-40, 0.5% sodium deoxycholate and 0.1% SDS, 500 nM
sodium orthovanadate plus 0.5 mM PMSF, and 1 mg/ml of antipain
and leupeptin) eluted in 13 protein sample buffer, separated by
SDS-polyacrylamide gel electrophoresis and subjected to Western
blot as described above.
Immunocytochemistry
Rat mesangial cells were cultured for 24 hours in glass cover-
slips and treated as described. Cells were fixed with cold methanol
Fig. 2. Effect of dexamethasone (DX) on NOS2 mRNA stability. Rat
mesangial cells (RMC) were treated with LPS (10 mg/ml) 1 TNF-a (100
ng/ml) (L/T) for 24 hours with or without DX (1026 M). After the addition
of 10 mg/ml actinomycin D (ActD) total RNA was extracted at the
indicated time points and hybridized to a 32P-labeled NOS2 probe as
described in the Methods section. The ratios of NOS2/28 S ribosomal
mRNA levels for every time point after ActD addition were obtained by
densitometric analysis and are represented in arbitrary units with respect
to the values obtained at zero time for every experimental condition. The
data are means 6 SE from two independent experiments. Where error bars
are not visible they are smaller than the data point. Symbols are: (E) L/T;
() DX 1 L/T.
Fig. 3. Effect of dexamethasone (DX) and RU-486 on NOS2 transcrip-
tion in rat mesangial cells (RMC) treated with LPS and TNF-a. RMC
were transfected with 388 bp (f; 2380-piNOS-LUC), 720 bp (o; 2720-
piNOS-LUC) or 720 bp with NF-kB mutated (u; 2720(NF-kB mut)-
piNOS-LUC) fragments of the 59 flanking regulatory region of rat NOS2
gene. Transfected cells were stimulated with vehicle (CT), LPS (10 mg/ml)
1 TNF-a (100 ng/ml), (L/T) or DX (1026 M) 1 L/T during 48 hours After
assaying for luciferase activity and/or lacZ, the luciferase relative light
units were normalized by lacZ or Renilla luciferase activity and protein
amount and the data were reported as relative luciferase units. Results are
means 6 SEM of three independent experiments, each performed in
duplicate plates. *P , 0.05 versus CT, **P , 0.05 versus L/T treatment of
RMC transfected with –720-piNOS-LUC, #P , 0.05 versus CT and versus
L/T treatment of RMC transfected with 2720-piNOS-LUC, ##P , 0.05
versus L/T treatment of RMC transfected with 2380-piNOS-LUC.
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during 10 minutes at 220°C. After three washes with PBS, the
slides were blocked with 10% of normal rabbit serum in PBS plus
2% bovine serum albumin (BSA). Cells were incubated for one
hour with the primary antibody (anti-p65 diluted 1:500 in 3%
BSA). After three washes with PBS, cells were incubated one hour
with a fluorescein isothiocianate-conjugated secondary antibody
(Amersham) in the dark. The nonincorporated antibody was
washed with PBS and coverslips were mounted into slides with a
drop of PermaFluor (Lipshaw Immunon, Pittsburgh, PA, USA).
Slides were visualized with a fluorescence microscope.
Statistical analysis
Every experimental condition was duplicated within each ex-
periment and each experiment was performed at least three times.
Comparisons were made with analysis of variance followed by
Dunnett’s modification of the t-test, whenever comparisons were
made with a common control, and the unpaired two-tailed
Student’s t-test was used for other comparisons. This test was used
whenever the number of total observations allowed to and after
performing a Kolmogorov-Smirnov test to confirm the normal
distribution of the data. When the number of observations was
insufficient to perform adequate parametric tests, non-parametric
tests were employed (Kruskal-Wallis). The level of a statistically
significant difference was defined as P , 0.05.
RESULTS
Dexamethasone inhibition of LPS/TNF-a-induced-NOS2 mRNA
expression in rat mesangial cells involves the glucocorticoid
receptor
As we have previously reported, DX inhibits NOS2 mRNA
expression induced by LPS/TNF (L/T) in a concentration- and
time-dependent fashion [15]. In order to understand the mecha-
nism of DX inhibition we evaluated the involvement of the
glucocorticoid receptor (Gr) in this process. As shown in Figure 1,
when rat mesangial cells were treated with DX, an 80 to 90%
reduction of the L/T-induced NOS2 transcript levels was detected.
Simultaneous addition of the glucocorticoid receptor antagonist
RU-486 abolished the effect of DX, thus demonstrating the
participation of Gr in the DX pathway. Neither DX nor RU-486
alone induced the expression of NOS2.
Dexamethasone inhibits NOS2 mRNA expression by a direct
transcriptional effect
In experiments designed to test the influence of DX on the
stability of the NOS2 transcript elicited by a combination of LPS
and TNF-a in RMC, we found that DX prolonged the half-life of
NOS2 mRNA slightly more than two hours (Fig. 2). These data
excluded mRNA destabilization as a potential mechanism by
which DX could be exerting its inhibitory effect on NOS2 mRNA
Fig. 4. Time course of NF-kB activation in rat mesangial cells induced with LPS1TNF-a. (A) Mesangial cells were incubated with LPS (10 mg/ml) 1
TNF-a (100 ng/ml) for the indicated periods of time. Nuclear protein extracts were obtained as described in the Methods section and analyzed by EMSA
using the NF-kB binding oligonucleotide from the rat NOS2 59 flanking region as a probe. Data are representative of four independent experiments.
(B) Supershift assays were carried out using the indicated antibodies against distinct proteins of the NF-kB protein family or no additions (CT).
Antibodies were used at 1 mg/ml. Competition assays (200-fold excess of unlabeled oligonucleotide) and an unrelated competitor oligonucleotide were
used to ensure the specificity of the bands (not shown). The position of the NF-kB complexes and that of a nonspecific complex (NS) is indicated by
arrows. Shown is a representative of three independent experiments.
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expression and suggested a transcription-inhibitory effect of DX.
To gain insight into the transcriptional regulation of rat NOS2 we
cloned a 727 bp fragment from the 59 regulatory region of rat
NOS2 obtained as specified in the experimental section. The
nucleotide sequence of this fragment (Genbank accession number
U61282) shares 98%, 89% and 64% identity with the reported
sequences of the corresponding regions from the rat [24], murine
[10, 11] and human [12] promoters, respectively. Sequences
complying for the consensus sequences of the TATA box, Oct-1,
NF-IL-6, NF-kB and TNF-RE [28] all included in the 388 bp
fragment, are 100% conserved in the rat sequence when com-
pared to the murine promoter. The 727 bp fragment included
three additional fully conserved g-IRE sites and a less well
conserved AP-1 site.
We next performed a functional characterization of this 59
flanking region. In RMC transfected with 380-piNOS-LUC and
720-piNOS-LUC, the combination of LPS and TNF-a induced a
significant increase in luciferase activity (Fig. 3). This increase was
markedly greater in the case of 720-piNOS-LUC. DX was able to
completely prevent L/T-stimulated luciferase activity observed in
the case of 380-piNOS-LUC and significantly abrogated the effect
of L/T on the promoter activity of the 720-piNOS-LUC construct
(Fig. 3). This inhibitory effect of DX was prevented by the
addition of the glucocorticoid receptor antagonist, RU-486 (Fig.
3). Transfection of RMC with a short construct of 97 nucleotides
which included the TATA box but not the NF-kB element showed
no response to LPS, TNF-a or their combination (N 5 2, data not
shown).
To explore the potential involvement of NF-kB in LPS/TNF-
induced activation, we carried out experiments with RMC trans-
fected with the construct kB(x3)-con A-LUC. We observed that
LPS and TNF-a increased luciferase activity threefold in these
cells, and that this activation was markedly abrogated both by DX
and PDTC, a well-characterized inhibitor of NF-kB activation
(N 5 2, data not shown). When RMC were transfected with a
plasmid where the NF-kB cis-regulatory sequence had been
mutated [720 (NF-kB mut)-piNOS-LUC], no increment in lucif-
erase activity over basal levels was observed in either control or
induced RMC (Fig. 3). Taken together, these results indicate that
NF-kB activation is necessary for NOS2 transcription in RMC and
that this activation could be potentially modulated by DX. Thus,
we investigated the role of DX in the pattern of NF-kB binding
activity under the experimental conditions previously described.
Treatment of RMC with L/T promotes activation of NF-kB
Electrophoretic mobility shift assays (EMSAs), using oligonu-
cleotide pairs with the kB sequence of the rat NOS2 promoter,
indicated a clear increment in the binding activity of this tran-
scription factor in RMC (Fig. 4A). This phenomenon could be
observed as early as 15 minutes after exposure of RMC to L/T and
it reached its peak after six hours with a slight decline after eight
hours, an observation fully consistent with the pattern of NOS2
mRNA expression and NO2
2 accumulation previously described
[15]. Competition with an excess of unlabeled oligonucleotide
completely abolished the detection of the complex (Fig. 6), while
the inclusion of an oligonucleotide containing the consensus
sequence for an unrelated transcription factor (SP-1) did not
interfere with formation of the complex (Fig. 6).
To identify the specific subunits involved in the formation of the
active NF-kB dimer in RMC treated with L/T, EMSAs were
performed in the presence of antibodies against the subunits p50,
p65 and c-Rel, which have been shown to participate in the
formation of the NF-kB dimer implicated in the activation of the
NOS2 promoter [29, 30]. As shown in Figure 4B, incubation with
anti-p65 or anti-p50 antibodies induced a clear supershift. This
effect was more intense when both antibodies were used together.
However, the presence of an antibody directed against c-Rel
shifted only a minor proportion of the complex (Fig. 4B). A
combination of anti-c-Rel and anti-p50 induced a supershift that
was significantly less evident than when the combination of
anti-p65 and anti-p50 was used. Therefore, our data suggest a
major role for the p50/p65 components in L/T-induced NF-kB
activation in RMC. Incubation with an antibody directed against
c-jun had no effect on the electrophoretic mobility of the complex.
Dexamethasone inhibits NF-kB activation in a time-dependent
fashion through its interaction with the glucocorticoid receptor
As depicted in Figure 5, EMSAs performed in nuclear extracts
from RMC stimulated with L/T for six hours clearly showed that
DX was able to inhibit NF-kB activation. This effect was partially
reversed by RU-486, suggesting the need for the interaction
between DX and the Gr for the inhibition to occur. Interestingly,
DX-induced inhibition was clearly time-dependent (Fig. 6), being
more intense when RMC had been pre-incubated for two hours
with the drug (63% inhibition) than when the latter was added
either at the same time or two hours after the addition of L/T
Fig. 5. Lipopolysaccharide (LPS) 1 TNF-a-induced NF-kB-binding ac-
tivity in rat mesangial cells (RMC) is repressed by dexamethasone (DX)
and dependent on the glucocorticoid receptor. RMC were treated during
six hours with: vehicle; L/T (LPS (10 mg/ml) 1 TNF-a (100 ng/ml); DX
(1026 M); RU-486 (1026 M); DX 1 L/T; RU-486 1 L/T and RU-486 1 DX
1 L/T as indicated. Abbreviations are in the legend to Figure 1. Nuclear
extracts were obtained as described in the Methods section and 7 mg of
protein were analyzed by EMSA using the NF-kB binding oligonucleotide
from the rat NOS2 sequence as a probe. Results are representative of
three independent experiments.
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(42% and 25% inhibition, respectively). In contrast, PDTC had a
significant inhibitory effect (more than 70% inhibition) at all
time-points studied. These observations again show good corre-
lation with the results on NOS2 mRNA levels and NO2
2 accu-
mulation previously reported [15].
Dexamethasone induces the expression of IkB-a mRNA and
protein and promotes its association with p65 in the cytoplasm
of rat mesangial cells treated with LPS and TNF-a
To gain insight into the mechanism of DX-mediated inhibition
of NF-kB activation, we explored whether the mRNA expression
of its inhibitory subunit, IkB, could be modified by the presence of
DX. As shown in Figure 7A, treatment of RMC with L/T
increased IkB-a mRNA levels after an incubation period of 30
minutes to one hour. However, when cells were treated with L/T
in the presence of DX, the IkB-a transcript was detectable as
early as 15 minutes. This effect of DX could be due to its ability
to induce IkB-a in RMC, as shown in Figure 7B.
After an appropriate stimulus, the IkB protein is known to
undergo phosphorylation and subsequent proteolytic degradation,
allowing the other two subunits of the NF-kB complex (that is,
p50 and p65) to translocate to the nucleus where transcription of
the target gene is activated [31]. Hence, we designed experiments
to address whether Dx is modulating this process, by increasing
IkB levels and thus preventing NF-kB nuclear translocation. As
depicted in Figure 8, treatment of RMC with L/T resulted in
decreased IkB-a protein levels in the cytoplasm that was most
apparent after 30 minutes of stimulation (Fig. 8A, left panel) and
correlated well with a significant increment of p65 protein levels in
the nucleus (Fig. 8B, left panel). When cells were pre-treated with
DX the levels of IkB-a were consistently higher (Fig. 8A, right
panel) and the appearance of nuclear p65 was significantly
delayed (Fig. 8B, right panel).
In this context it was of interest to determine if DX could
modify the levels of IkB complexed with p65, as this could reflect
more precisely if DX-induced IkB transcript levels were involved
in hindering the translocation of NF-kB to the nucleus. For this
purpose we designed a protocol in which the association of the
IkB-a and p65 subunits was evaluated by Western blot after two
subsequent co-immunoprecipitation steps using specific antibod-
ies directed either against IkB-a or p65. Under control conditions
a detectable fraction of IkB-a appears associated with p65 (Fig. 9,
upper panel). Treatment of RMC with L/T resulted in a marked
decrease in the amount of p65 which co-precipitates with IkB-a
(Fig. 9, lower panel). Conversely, the amount of IkB-a that can be
co-precipitated by the anti-p65 antibody is nearly undetectable
(Fig. 9, upper panel). By contrast, treatment of RMC with DX
induced a significant increment in the amount of p65 which
appears associated with IkB-a in the cytoplasm (Fig. 9, lower
panel). Also, almost all IkB-a can be co-immunoprecipitated by
the anti-p65 antibody. Pre-incubation with DX in cells treated
with L/T results in the retention of p65 in the cytoplasm as a
consequence of its association with IkB-a (Fig. 9). This behavior
is further illustrated in Figure 10 in which the subcellular local-
ization of p65 is demonstrated by fluorescence microscopy. Under
control conditions most of the p65 immunoreactivity is localized
in the cytosol. Treatment of RMC with L/T induced the translo-
cation of p65 to the nuclear compartment. This translocation was
Fig. 6. Effects of dexamethasone (DX) and
pyrrolidine dithiocarbamate (PDTC) on NF-kB
activation. Rat mesangial cells (RMC) were
treated as follows for the indicated periods of
time (in hours): Vehicle; L/T (LPS (10 mg/ml)
1 TNF-a (100 ng/ml)); DX (1026 M,); PDTC
(100 mM); DX 1 L/T and PDTC 1 L/T.
Abbreviations are in the legend of Figure 1.
Nuclear extracts were analyzed by EMSA as
described above. Data are representative of
three independent experiments. Competition
assays (200-fold excess of unlabeled
oligonucleotide) and an unrelated competitor
oligonucleotide (SP-1) were used to ensure the
specificity of the bands.
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completely abrogated in the presence of DX. Furthermore,
treatment of RMC with the Gr antagonist RU-486 completely
abolished the effect of DX, thus allowing the detection of the p65
immunoreactive signal in the nucleus.
Taken together, results shown in Figures 7, 8, 9 and 10
demonstrate that a fundamental mechanism by which DX inhibits
NF-kB-mediated transcriptional activation in RMC is by the
up-regulation of the IkB-a mRNA and protein levels. As a
Fig. 7. Effect of dexamethasone (DX) on IkB-a mRNA expression in rat mesangial cells (RMC) stimulated with LPS 1 TNF-a. (A) RMC were treated
with L/T (LPS (10 mg/ml) 1 TNF-a (100 ng/ml) with or without DX (1026 M) for the indicated time periods. Total RNA was extracted and 10 mg
analyzed by Northern blot. The blot was probed first with MAD-3-IkB-a cDNA (upper panel). and reprobed with b-actin cDNA (middle panel). Shown
in the lower panel is the densitometric analysis of the IkB-a expression time-course in the absence (open circles) and presence (black triangles) of DX
after correction by the expression of b-actin. The data are representative of two independent experiments. (B) Cells were treated with DX (1026 M) for
the indicated time periods. Total RNA was extracted and 10 mg analyzed by Northern blot. The blot was probed first with MAD-3-IkB-a cDNA (upper
panel). and reprobed with b-actin cDNA (middle panel). Shown in the lower panel is the densitometric analysis of IkB-a mRNA expression after
correction by the expression of b-actin. The data are representative of two independent experiments.
Fig. 8. Effects of dexamethasone (DX) on IkB-a protein levels and nuclear localization of p65 in rat mesangial cells (RMC). RMC were pretreated
with DX (1026 M) for two hours and/or stimulated with LPS (10 mg/ml) 1 TNF-a (100 ng/ml) (L/T) for the indicated periods of time. Cytoplasmic (A)
and nuclear (B) extracts were isolated and analyzed by immunoblotting with anti-IkB-a or anti-p65 antibodies, respectively. Data are representative of
two independent experiments.
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consequence of this increase, the NF-kB complex (p65 in the
results shown) is retained in the cytoplasm, a circumstance that
results in very low levels of translocation into the cell nucleus and
hence in markedly diminished transcriptional activation.
DISCUSSION
In this work we analyze some of the potential mechanisms
responsible for the inhibitory effect of DX on the expression of
NOS2 mRNA induced by LPS and TNF-a in RMC. Our results
show that DX modulates NOS2 gene expression by acting at
multiple levels. Whereas it slightly prolongs the NOS2 mRNA
half-life, experiments in RMC transfected with promoter con-
structs of the rat NOS2 gene clearly showed that DX inhibited this
promoter activity. Furthermore, we established the participation
of the NF-kB transcription factor and its inhibitory subunit IkB as
crucial targets in the mechanism by which DX inhibits NOS2
expression.
Dexamethasone inhibits the expression of many pro-inflamma-
tory genes [32], and the molecular basis of this effect has been
recently characterized. Research performed on the structure and
function of the glucocorticoid receptor family identified general
mechanisms for the transcriptional regulation exerted by these
agents, which implied the participation of the HSP90-Gr complex
and its activation after ligand binding [33]. Activation of Gr
resulted in its translocation to the nucleus where it bound to
specific cis-regulatory regions of various genes. However, analysis
of the 59 flanking regulatory regions from several proinflamma-
tory genes whose transcription was clearly regulated by DX
showed the absence of these sequences. Hence, alternative expla-
nations supported by experimental data were proposed, including
the interaction between Gr and other transcription factors such as
AP-1 or NF-kB [32, 34–37], whose cognate cis-regulatory se-
quences were present in the genes studied. Finally, another level
of complexity has been recently added, since a direct modulation
of the activation of the paradigmatic proinflammatory transcrip-
tion factor NF-kB by DX has been observed [31]. Thus, it appears
as if the effect of DX on gene expression may utilize one or more
pathways depending upon the gene and the cell type or tissue
involved, from which multiple levels of interaction may result, the
final balance being the induction or repression of a particular
gene.
Dexamethasone has inhibitory effects on NOS2 mRNA expres-
sion in several cell types [38, 39]. However, contradiction has
arisen regarding the potential molecular mechanisms of this
inhibition. In smooth muscle cells, DX modestly inhibited the
transcriptional rate of NOS2 mRNA synthesis while it doubled its
half-life [39]. Availability of the promoter region of NOS2 has
made it possible to extend the mechanistic investigation of NOS2
expression. Two general concepts that have emerged from the
functional analysis of these promoters include the profound
differences in structure-function relationships between human
and murine cells [40] and the presence of two main regulatory
regions in the murine NOS2 promoter: one responsive to IFN-g
that could resemble an enhancer, and the other sensitive to LPS,
closer to the transcriptional start site [10, 11]. In addition, the
functional relevance of the cis-regulatory element NF-kB has
been analyzed in murine macrophages [29] and rat vascular
smooth-muscle cells [41]. Since the molecular characterization of
NOS2, several groups including ours have analyzed the effect of
DX on NOS2 protein and mRNA expression in rat mesangial cells
[14, 15, 42]. The functional characterization of the 59 flanking
regulatory region of NOS2 in cells of rat origin facilitates the
understanding of the DX-mediated effects. In this study we show
that RMC transfected with two fragments of different length of
this region, an NF-kB tandem and a fragment containing a
mutation for the NF-kB site, clearly establish that NF-kB is a
transcription factor necessary, but not sufficient, for full promoter
activity. The interaction of other transcription factors with the
region of the promoter included in the construct of greater length
may actually enhance NF-kB-mediated transcriptional activation
and, therefore, should be the object of further analysis. Also, this
set of results suggested an inhibitory effect of DX on the
activation of NF-kB. Accordingly, DX is able to inhibit NF-kB
activity in a process dependent on the Gr and the temporal course
of this phenomenon correlates closely with the inhibition of NOS2
mRNA expression observed in previous studies [15]. In keeping
with these observations we have found that DX increases IkB
mRNA. This effect, as supported by experiments looking at the
temporal course of appearance of IkB-a and p65 proteins in
cytoplasmic and nuclear extracts and co-immunoprecipitation
assays of p65 and IkB-a plus immunocytological studies, results in
the persistent association of IkB-a with the activating subunits of
NF-kB, promoting its retention in the cytoplasm and hence
impeding its stimulus-dependent nuclear translocation. These
Fig. 9. Dexamethasone (DX) induces IkB-a
synthesis and association with p65. Rat
mesangial cells (RMC) were pretreated with
DX (1026 M) for two hours and stimulated with
L/T (LPS (10 mg/ml) 1 TNF-a (100 ng/ml)
during four hours. Two hundred micrograms of
cytoplasmic extracts were precleared and
immunoprecipitated using either pre-immune
serum (PS) or anti-IkB-a antibodies and
protein A/G agarose. Immunocomplexes were
precipitated, washed and eluted and the
supernatant was divided in two aliquots which
were re-immunoprecipitated with either anti-
p65 or anti-IkB-a antibodies.
Immunocomplexes were separated by SDS-
PAGE, transferred and analyzed by
immunoblotting. The data are representative of
three different experiments. Abbreviations are
in the legend to Figure 1.
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results agree with data obtained in some cell lines [43, 44] but are
in contrast with what has been described in endothelial cells or rat
brain, where the physical interaction between the glucocorticoid
receptor and NF-kB seems to be the fundamental mechanism of
the glucocorticoid-mediated repression [45, 46]. Different results
have been found in other studies looking at the mechanism of DX
inhibition of NOS2 induction. In a transformed human cell line a
similar inhibition of NF-kB by DX was reported but with no
apparent effect on IkB induction [47]. In RMC treated with
IL-1b, transcriptional (including deactivation of NF-kB), post-
transcriptional (mRNA stabilization) and post-translational ef-
fects of DX were found [48]. This diversity of data emphasizes the
importance of characterizing each cell system with each particular
stimulus, in order to identify potential pathways of therapeutic
intervention in inflammatory processes.
In view of our study, it can be proposed that a main regulatory
checkpoint responsible for the inhibitory effect of DX on NOS2
expression takes place at the transcriptional level and that it is
significantly mediated through the induction of IkB-a. The fact
that pretreatment of RMC with DX and the subsequent induction
of IkB-a expression has a stronger effect than co-treatment or
post-treatment with the drug is consistent with this contention,
since higher intracellular levels of this inhibitory subunit would
better prevent NF-kB activation, by sequestration of the complex
in the cytoplasm.
It is well known that NO plays a critical role in the pathophys-
iology of septic shock. The necessity of pretreating cells with DX
in order to efficiently suppress NOS2 expression and NO synthe-
sis, based on the above proposed mechanisms, might help to
explain the reported lack of effect of massive glucocorticoid
administration in the final stages of sepsis [49]. Future studies
should then focus on obtaining therapeutic tools whose main
mechanism of action is distal to the establishment of intracellular
signals triggered by the proinflammatory stimuli.
Fig. 10. Dexamethasone (DX) treatment
retains p65 in the cytoplasm of L/T-stimulated
rat mesangial cells (RMC). RMC were plated
into coverslips and treated with vehicle (CT),
DX (1026 M, 2 hr) and DX (1026 M, 2 hr) 1
RU-486 (10 mM, 2 hr) (DX1RU) with or
without LPS (10 mg/ml,1 hr) 1 TNF-a (100
ng/ml, 1 hr) (L/T). After treatment, cells were
fixed and the intracellular localization of p65
was determined by indirect immunofluorescence
with an anti-p65 antibody. Microphotographs
represent typical fields of RMC where
immunofluorescent p65 is clearly visible.
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APPENDIX
Abbreviations used in this article are: RMC, rat mesangial cells; DX,
dexamethasone; LPS, lipopolysaccharide; TNFa, tumor necrosis factor
alpha; L/T, lipopolysaccharide plus TNFa; NO, nitric oxide; NOS, nitric
oxide synthase; NOS1, neuronal isoform of NOS; NOS2, inducible isoform
of NOS; NOS3, endothelial isoform of NOS; rHuTNF, recombinant
human tumor necrosis factor; a-32P, deoxycytidine 59-triphosphate; RU-
486, Mifepristone; PDTC, pyrrolidine dithiocarbamate; RT-PCR, reverse
transcriptase—polymerase chain reaction; EMSAS, electrophoretic mo-
bility shift assays; BSA, bovine serum albumin; Gr, glucocorticoid recep-
tor.
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